lba41 - leap-005: phase ii study of lenvatinib plus pembrolizumab
Published 3 years ago • 46 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
2:57
esmo 2020 highlights on lenvatinib plus pembrolizumab in advanced solid tumours: leap-005
-
1:22
discussing the phase ii study of lenvatinib/pembrolizumab in metastatic ccrcc
-
3:03
promising results from the gastric cancer cohort of leap-005
-
6:05
leap-004: lenvatinib pembrolizumab for patients with advanced melanoma and confirmed progressi...
-
1:16
dr. lwin on the results of the leap-005 trial in advanced solid tumors
-
2:21
lba44 - lenvatinib plus pembrolizumab for advanced melanoma
-
2:41
leap-011: exploring first-line pembrolizumab lenvatinib for advanced urothelial carcinoma
-
2:44
leap-015: lenvatinib pembrolizumab mfolfox6 in advanced/met gastroesophageal adenocarcinoma
-
0:56
treating patients with melanoma who progressed on anti-pd-l1 with lenvatinib and pembrolizumab
-
1:06
leap-011: first-line pembrolizumab plus lenvatinib for uc
-
1:22
dr. zamarin on the role of pembrolizumab in endometrial cancer
-
6:38
lenvatinib plus pembrolizumab for advanced melanoma that progressed on a pd-1 or pd-l1 inhibitor...
-
3:39
keynote-716: pembrolizumab for patients with high-risk stage ii melanoma
-
0:41
keystep-004: combination immunotherapy with lenvatinib for advanced hcc
-
1:00
rationalizing use of pembrolizumab/bevacizumab in recurrent ovarian cancer
-
0:55
rajni kannan on managing the side effects of ipilimumab and vemurafenib
-
1:02
dr. hellmann on nivolumab in combination with ipilimumab for small cell lung cancer
-
1:01
biomarkers evolve for treatment of lung cancers
-
0:42
dr. zsiros discusses pembrolizumab triplet in recurrent ovarian cancer